A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)
Enrolling By Invitation
18 years - 99 years
All
Phase
1
8 participants needed
1 Location
Brief description of study
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the observed adverse events, including potential dose-limiting toxicities (DLT).
Subjects will be recruited for this study from the practices of Penn Medicine.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: acute lymbhoblatic leukemia,non-hodgkin lymphoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 843128
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
